EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zealand Pharma AS's Enterprise Value is €883 Mil.
Zealand Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €843 Mil. Therefore, Zealand Pharma AS's EV-to-FCF for today is 1.05.
The historical rank and industry rank for Zealand Pharma AS's EV-to-FCF or its related term are showing as below:
HAM:22Z'
s EV-to-FCF Range Over the Past 10 Years
Min: -111.49 Med: -10.25 Max: 80.57
Current: 1.05
During the past 13 years, the highest EV-to-FCF of Zealand Pharma AS was 80.57. The lowest was -111.49. And the median was -10.25.
HAM:22Z's EV-to-FCF is ranked better than 77.48% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs HAM:22Z: 1.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zealand Pharma AS's PE Ratio (TTM) for today is calculated as:
Zealand Pharma AS's share price for today is €38.40.
Zealand Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.928.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zealand Pharma AS EV-to-FCF Related Terms
Zealand Pharma AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zealand Pharma AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's EV-to-FCF falls into.
Zealand Pharma AS's current Enterprise Value is €883 Mil.
Zealand Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €843 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (HAM:22Z) has a EV-to-FCF of 1.05 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #75 out of 333 companies in the Biotechnology industry, placing it in the top 22.5%.
Is Zealand Pharma AS's EV-to-FCF too high?
Zealand Pharma AS's current EV-to-FCF is 1.05. The Biotechnology industry median EV-to-FCF is 15.57. Zealand Pharma AS's value of 1.05 is 93.3% below this industry median. Based on the distribution chart, Zealand Pharma AS ranks #75 out of 333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #75 out of 333 companies for EV-to-FCF. This places Zealand Pharma AS in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.57. Zealand Pharma AS's value of 1.05 is 93.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current EV-to-FCF of 1.05 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current EV-to-FCF is 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (HAM:22Z) is currently considered Possible Value Trap. The stock's GF Value™ is €1,626.53, compared to a current price of €38.40 — trading 97.6% below its estimated fair value. The current EV-to-FCF is 1.05 and 93.3% below the Biotechnology industry median of 15.57. Zealand Pharma AS's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zealand Pharma AS (HAM:22Z), the current EV-to-FCF is 1.05 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (HAM:22Z) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of €38.40 is trading 97.6% below its estimated GF Value™ of €1,626.53.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for HAM:22Z:
EV-to-FCF: 1.05
GF Value™: €1,626.53 vs. price of €38.40 (97.6% below fair value)
Industry Position: 93.3% below the Biotechnology median (#75 of 333)
No single metric tells the full story. See the HAM:22Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
68GF Score
Get the complete analysis for HAM:22Z
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:22Z has been successfully added to your 
